Monograph: Raltegravir Potassium

Raltegravir Potassium

Die Inhalte stehen nur registrierten Benutzern zur Verfügung.

Sie sind zum ersten mal hier und möchten die Datenbank 10-Tage kostenlos testen, dann registrieren Sie sich einmalig. Nach der Registrierung melden Sie sich mit Ihrem Benutzernamen und Passwort an.

Sie sind bereits bei DrugBase registriert und möchten diese Datenbank 10-Tage kostenlos und unverbindlich testen? Dann melden Sie sich mit Ihren Zugangsdaten an und wählen Sie anschließend die Datenbank, die Sie testen möchten.

Full Title

Raltegravir Potassium

Generic Name

Raltegravir Potassium

Chemical Name

...

INV Number

...

ATC-Code

...

Classification

CAS Number

...

Introduction

Introduction

...

...

Description

...

...

Uses

Uses

...

Treatment of HIV Infection

...

Antiretroviral-naive Adults

...

Clinical Experience

...

Antiretroviral-experienced Adults

...

Clinical Experience

...

Pediatric Patients

...

Clinical Experience

...

Postexposure Prophylaxis following Occupational Exposure to HIV

...

Postexposure Prophylaxis following Nonoccupational Exposure to HIV

...

...

Dosage and Administration

Dosage and Administration

...

Administration

...

Chewable Tablets

...

Film-coated Tablets

...

Powder for Oral Suspension

...

Dosage

...

Adult Dosage

...

Treatment of HIV-1 Infection in Antiretroviral-naive Adults

...

Treatment of HIV-1 Infection in Antiretroviral-experienced Adults

...

Postexposure Prophylaxis following Occupational Exposure to HIV

...

Postexposure Prophylaxis following Nonoccupational Exposure to HIV

...

Pediatric Dosage

...

Treatment of HIV-1 Infection

...

Table 1. Recommended Dosage of Raltegravir Oral Suspension (Isentress®) in Full-term Neonates (Birth to 4 Weeks of Age) Weighing 2 kg or More1

...

Table 2. Recommended Dosage of Raltegravir Oral Suspension or Chewable Tablets (Isentress®) in Pediatric Patients 4 Weeks of Age or Older Weighing 3 to less than 25 kg1

...

Table 3. Recommended Dosage of Raltegravir Chewable Tablets (Isentress®) In Pediatric Patients Weighing 25 kg or More and Unable to Swallow the Film-coated Tablets1

...

Special Populations

...

Hepatic Impairment

...

Renal Impairment

...

Geriatric Patients

...

...

Cautions

Cautions

...

Contraindications

...

Warnings/Precautions

...

Sensitivity Reactions

...

Severe Skin and Hypersensitivity Reactions

...

Interactions

...

Musculoskeletal Effects

...

HIV-infected Individuals Coinfected with HBV or HCV

...

Immune Reconstitution Syndrome

...

Pharmacogenomics

...

Phenylketonuria

...

UGT1A1 Polymorphism

...

Specific Populations

...

Pregnancy

...

Lactation

...

Pediatric Use

...

Geriatric Use

...

Hepatic Impairment

...

Renal Impairment

...

Common Adverse Effects

...

...

Drug Interactions

Drug Interactions

...

Drugs Affecting or Metabolized by Hepatic Microsomal Enzymes

...

Drugs Affecting or Metabolized by Uridine Diphosphate-glucuronosyltransferases

...

Drugs Affected by P-glycoprotein Transport

...

α1-Adrenergic Blocking Agents

...

Anticoagulants

...

Apixaban, Betrixaban, Dabigatran, Edoxaban, and Rivaroxaban

...

Warfarin

...

Anticonvulsants

...

Carbamazepine

...

Eslicarbazepine

...

Ethosuximide and Lamotrigine

...

Oxcarbazepine, Phenobarbital, and Phenytoin

...

Valproic Acid

...

Antidepressants

...

Selective Serotonin-reuptake Inhibitors

...

Serotonin Modulators

...

Nefazodone and Trazodone

...

Tricyclic Antidepressants

...

Other Antidepressants

...

Bupropion

...

Antidiabetic Agents

...

Dapagliflozin and Saxagliptin

...

Metformin

...

Antifungal Agents

...

Itraconazole, Posaconazole, and Voriconazole

...

Antilipemic Agents

...

HMG-CoA Reductase Inhibitors

...

Lomitapide

...

Antimycobacterial Agents

...

Rifabutin

...

Rifampin

...

Rifapentine

...

Antiplatelet Agents

...

Antipsychotic Agents

...

Antiretroviral Agents

...

HIV Entry and Fusion Inhibitors

...

Enfuvirtide

...

Maraviroc

...

HIV Integrase Inhibitors

...

Dolutegravir

...

HIV Nonnucleoside Reverse Transcriptase Inhibitors (NNRTIs)

...

Doravirine

...

Efavirenz

...

Etravirine

...

Nevirapine

...

Rilpivirine

...

HIV Nucleoside and Nucleotide Reverse Transcriptase Inhibitors (NRTIs)

...

Lamivudine

...

Tenofovir

...

HIV Protease Inhibitors (PIs)

...

Atazanavir

...

Darunavir

...

Fosamprenavir

...

Lopinavir

...

Tipranavir

...

Benzodiazepines

...

Buspirone

...

Calcifediol

...

Calcium, Iron, Multivitamins, and Other Preparations Containing Polyvalent Cations

...

Calcium, Iron, and Multivitamins

...

Preparations Containing Polyvalent Cations

...

Cardiac Drugs

...

Antiarrhythmic Agents

...

β-Adrenergic Blocking Agents

...

Bosentan

...

Calcium-channel Blocking Agents

...

Eplerenone, Ivabradine, and Ranolazine

...

Colchicine

...

Corticosteroids

...

Systemic Corticosteroids

...

Dexamethasone

...

Betamethasone, Budesonide, Prednisone, and Prednisolone

...

Orally Inhaled or Intranasal Corticosteroids

...

Local Injections of Corticosteroids

...

Dronabinol

...

Ergot Alkaloids and Derivatives

...

Estrogens and Progestins

...

Estradiol, Estrogen, and Conjugated Estrogens

...

Ethinyl Estradiol and Norgestimate

...

Drospirenone, Medroxyprogesterone, and Progesterone

...

Flibanserin

...

GI Drugs

...

Antacids

...

Eluxadoline

...

Histamine H2-receptor Antagonists

...

Proton-pump Inhibitors

...

Sucralfate

...

Goserelin

...

HCV Antivirals

...

HCV Polymerase Inhibitors

...

Sofosbuvir

...

Sofosbuvir and Velpatasvir

...

Sofosbuvir, Velpatasvir, and Voxilaprevir

...

HCV Protease Inhibitors

...

Glecaprevir and Pibrentasvir

...

HCV Replication Complex Inhibitors

...

Elbasvir and Grazoprevir

...

Ledipasvir and Sofosbuvir

...

Immunosuppressive Agents

...

Leuprolide

...

Lofexidine

...

Macrolides

...

Opiates and Opiate Partial Agonists

...

Buprenorphine

...

Fentanyl

...

Methadone

...

Tramadol

...

Phosphodiesterase Type 5 Inhibitors

...

Selective β-adrenergic Agonists

...

Spironolactone

...

Suvorexant

...

Testosterone

...

Zolpidem

...

...

Advice to Patients

Advice to Patients

...

...

Preparations

Preparations

...

Raltegravir Potassium

...

...

Common general statement Elements

Additional Information

...

...

References

References

...

...

Copyright

AHFS® Drug Information. © Copyright, 1959-2020, Selected Revisions September 28, 2020. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

† Use is not currently included in the labeling approved by the US Food and Drug Administration.

Quelle

AHFS Drug Information